A PYMNTS Company

AbbVie, Allergen Sign Deal With FTC

By  |  March 18, 2020

AbbVie and Allergan announced Tuesday, March 17, that they signed a consent decree with the US Federal Trade Commission that will commit the companies to selling some properties if they commence a planned merger. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    As previously announced, the companies plan to sell brazikumab, an experimental Crohn’s disease and ulcerative colitis treatment, to AstraZeneca and pancreatic treatment Zenpep to Nestlé. 

    Tuesday’s announcement also stated that Nestlé plans to purchase Viokace, a similar product. The companies stated they expect the deal to close in May.

    Full Content: Market Watch

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.